Please login to the form below

Not currently logged in
Email:
Password:

finerenone

This page shows the latest finerenone news and features for those working in and with pharma, biotech and healthcare.

Xarelto and Eylea continue to dominate Bayer's pharma sales

Xarelto and Eylea continue to dominate Bayer's pharma sales

They include five candidates in phase III trials: copanlisib for non-Hodgkin lymphoma, ODM-201 for hormone-sensitive prostate cancer, finerenone for diabetic kidney disease, vilaprisan for uterine fibroids and endriametosis

Latest news

More from news
Approximately 1 fully matching, plus 4 partially matching documents found.

Latest Intelligence

  • Heart failure therapy embarks on a new era Heart failure therapy embarks on a new era

    Bayer recently started three late-stage trials of its HF candidate finerenone - a mineralocorticoid drug designed as a safer replacement for older drugs in the class such as eplerenone and spironolactone,

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Accession

Accession was a born from a passion and a vision. A passion to harness the power of market access to...

Latest intelligence

From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality
How pharma is progressing their commitment in patient engagement...
Cuttsy+Cuttsy awarded CPD Platinum by the IPA
Four years after being awarded Gold for their continuous professional development (CPD) Cuttsy+Cuttsy (C+C) have reached another milestone and been awarded Platinum accreditation....
Breaking Bad
Six behaviours separate the good brand teams from the bad...

Infographics